

TABLE 1 esupplement Empiric treatment in different categories

	Received MRSA covering empiric treatment (n=24)	Did not receive MRSA covering empiric treatment (n=107)	P-value
Infection type			0.176
Abscess	5 (11.4 %)	39 (36.4 %)	
Bacteremia	0	1 (0.9 %)	
Cellulitis	1 (4.2 %)	6 (5.6 %)	
Fresh wound	3 (12.5 %)	5 (4.7 %)	
Furunculosis	3 (12.5 %)	3 (2.8 %)	
Respiratory and head and neck infection	3 (12.5 %)	7 (6.5 %)	
Secondary infection of a chronic wound	3 (12.5 %)	16 (31.4 %)	
Surgical site infection	4 (16.7 %)	26 (24.3 %)	
Urinary tract infection	1 (4.2 %)	3 (2.8 %)	
Unknown	1 (4.2 %)	1 (0.9 %)	
Born abroad (n=129)*	1 (4.2 %)	14 (13.3 %)	0.301
Medical history	24 (8.6 %)	107 (38.2 %)	0.941
CCI 0	13 (54.2 %)	53 (49.5 %)	
CCI 1-4	7 (29.2 %)	28 (26.2 %)	
CCI ≥5	2 (8.3 %)	15 (14.0 %)	
Unknown	2 (8.3 %)	11 (10.3 %)	
Hospitalization due to MRSA infection (n=107)*	4 (20.0 %)	39 (44.8 %)	0.041
Age	24 (8.6 %)	107 (38.2 %)	0.201

<18 years	6 (25.0 %)	14 (13.1 %)	
18 - 64 years	15 (62.5 %)	66 (61.7 %)	
≥65 years	3 (12.5 %)	27 (25.2 %)	
Gender, male	16 (66.7 %)	53 (49.5 %)	0.129
HCW	1 (4.2 %)	10 (9.3 %)	0.688
Season of infection	24 (8.6 %)	107 (38.2 %)	0.655
January - March	8 (33.3 %)	30 (28.0 %)	
April - June	6 (25.0 %)	18 (16.8 %)	
July - September	7 (29.2 %)	38 (35.5 %)	
October - December	3 (12.5 %)	21 (19.6 %)	

*Number of cases with background data in question available and empiric treatment given known